Adler S, et al. - The purpose of this study was to investigate the everyday imunosuppressive treatment (IS) prescription patterns and clinical courses of lung function during and after therapy in order to ameliorate the progression of interstitial lung disease in systemic sclerosis (SSc-ILD). The prescription of IS in SSc-ILD was broad. It was noted that clusters of clinical and functional characteristics assisted in individualised treatment. Distinguished decision-making, encompassing either watchful waiting and close monitoring was favoured in the early stages or start of immunosuppressive treatment in moderately impaired lung function. The illustration of advantages of specific IS was found to be difficult owing to confounding by indication. Findings did not support the liberal use of glucocorticoid (GC) in SSc-ILD.